TOP1 and cancer: TDP1 inhibitors could potentiate the anticancer activity of TOP1 inhibitors (Pommier et al., 2014; Hu et al., 2016; Laev et al., 2016) and as such, they would represent a new therapeutic class that could potentially be used for the treatment of cancer in combination with current TOP1 inhibitors (Interthal et al., 2005; Beretta et al., 2010; Comeaux and van Waardenburg, 2014; Gao et al., 2014).